Edesa Biotech filings document the formal disclosure record of a clinical-stage biotechnology issuer focused on host-directed therapeutics for immuno-inflammatory diseases. Recent Form 8-K reports cover clinical-study disclosures for paridiprubart in Acute Respiratory Distress Syndrome, operating and financial results, material-event updates and agreements connected to funded development work.
The company’s filings also address capital-structure matters, including common-share sales under at-the-market offering arrangements and related Form S-3 prospectus supplements. Proxy materials cover shareholder voting matters, board governance, executive compensation and equity-award disclosures for the public company.
Edesa Biotech, Inc. director and Chief Executive Officer Pardeep Nijhawan reported an indirect open-market purchase of Common Shares. On March 4, 2026, Pardeep Nijhawan Medicine Professional Corporation, an entity wholly owned by him, bought 10,000 Common Shares at a price of $4.2560 per share. Following this transaction, that entity was reported to hold 392,702 Common Shares indirectly.
As of the same date, Nijhawan also reported 627,813 Common Shares held directly. Indirect holdings were additionally reported as 32,609 Common Shares held by The New Nijhawan Family Trust 2015, 32,013 Common Shares held by The Digestive Health Clinic Inc., and 53,104 Common Shares held by 1968160 Ontario Inc., with beneficial ownership disclaimed except to the extent of his pecuniary interest.
Edesa Biotech, Inc. director and Chief Executive Officer Pardeep Nijhawan reported an indirect open-market purchase of 10,000 common shares on March 3, 2026 at a price per share of 3.63, through Pardeep Nijhawan Medicine Professional Corporation.
The filing also reports Nijhawan’s direct and additional indirect holdings in common shares, including positions held via The New Nijhawan Family Trust 2015, The Digestive Health Clinic Inc., and 1968160 Ontario Inc., with beneficial ownership disclaimed except to the extent of his pecuniary interest.
Edesa Biotech, Inc. director and Chief Executive Officer Pardeep Nijhawan reported open-market purchases of company common shares. On March 2, 2026, he bought 2,000 common shares directly at $2.00 per share and an additional 1,000 common shares indirectly at $2.2796 per share through Pardeep Nijhawan Medicine Professional Corporation.
Following these transactions, direct holdings stood at 627,813 common shares. Indirectly, entities associated with him held 372,702 common shares at Pardeep Nijhawan Medicine Professional Corporation, 32,609 common shares at The New Nijhawan Family Trust 2015, 32,013 common shares at The Digestive Health Clinic Inc., and 53,104 common shares at 1968160 Ontario Inc. The report notes that he disclaims beneficial ownership of these indirect holdings except to the extent of his pecuniary interest.
Edesa Biotech, Inc. reported that Point72 Asset Management, L.P., Point72 Capital Advisors, Inc. and Steven A. Cohen beneficially own 600,000 Common Shares, representing 7.2% of the class as of March 2, 2026.
The filing states the reported shares carry shared voting power and shared dispositive power of 600,000, and that Point72 Associates has the right to receive dividends or sale proceeds for more than 5% of outstanding Common Shares.
Velan Capital and affiliated entities have amended their Schedule 13D for Edesa Biotech, Inc., updating their reported ownership and capital structure details. The group now reports beneficial ownership of 834,700 common shares, or approximately 9.99% of Edesa’s outstanding shares, through various Velan funds and management entities. This includes 569,075 shares held by Velan Master, 250,000 shares held by Velan Opportunity II, and 15,625 shares held by Velan Horizon, some of which are issuable upon conversion of Preferred Shares subject to an ownership cap. Without this ownership limitation on the Preferred Shares, the reporting persons state they would collectively beneficially own 3,785,833 shares, or about 33.5% of the company’s common stock. The amendment also notes that previously issued warrants have expired worthless as of December 23, 2025.
Edesa Biotech’s major shareholder group led by Dr. Pardeep Nijhawan filed Amendment No. 9 to update their Schedule 13D. Dr. Nijhawan may be deemed to beneficially own 2,040,785 common shares, representing approximately 19.99% of Edesa’s outstanding common shares on a converted basis.
The filing details multiple restricted stock unit grants to Dr. Nijhawan in 2025 and early 2026, many issued in lieu of partial salary and bonus, as well as a larger 263,200-unit grant vesting over 12 and 36 months. On February 26, 2026, he bought 20,571 common shares at a weighted average price of $1.5789, and his professional corporation acquired 30,000 shares at a weighted average price of $2.2232, both using investment capital. The filing also describes a 19.99% beneficial ownership blocker on Series B-1 Preferred Shares.
Edesa Biotech, Inc.’s Chief Executive Officer Pardeep Nijhawan reported multiple recent transactions in the company’s common shares. He received a grant of 10,016 restricted share units that vested in full upon grant under the 2019 Equity Incentive Compensation Plan, at a stated price of $0.00 per share.
He also bought 20,571 common shares in open-market transactions at a weighted average price of $1.5789 per share and 30,000 common shares at a weighted average price of $2.2232 per share, including purchases held through Pardeep Nijhawan Medicine Professional Corporation. Additional share holdings are reported indirectly through The New Nijhawan Family Trust 2015, The Digestive Health Clinic Inc., and 1968160 Ontario Inc., with beneficial ownership disclaimed except to the extent of his pecuniary interest.
Edesa Biotech Chief Executive Officer Pardeep Nijhawan reported an equity compensation grant on common shares. On February 19, 2026, he acquired 82,236 restricted share units, which vested in full upon grant under Edesa’s 2019 Equity Incentive Compensation Plan, at a reported price of $0.00 per share. These RSUs were received in lieu of a portion of his cash bonus for the calendar year ending December 31, 2025. Following this award, Nijhawan directly owns 595,226 common shares, and additional common shares are held indirectly through entities such as Pardeep Nijhawan Medicine Professional Corporation, The New Nijhawan Family Trust 2015, The Digestive Health Clinic Inc., and 1968160 Ontario Inc., with beneficial ownership disclaimed except to the extent of his pecuniary interest.
Edesa Biotech reported additional positive Phase 3 results for its anti-TLR4 antibody paridiprubart in a 278-patient study. Across the full population, paridiprubart cut adjusted 28-day mortality to 24% versus 33% on placebo, a 27% relative risk reduction with strong statistical significance (p<0.001).
In a milder, 174-patient non-IMV subgroup, paridiprubart plus standard of care reduced adjusted 28-day mortality to 15% from 23%, a 35% relative risk reduction (p<0.005). Patients on paridiprubart also showed higher rates of clinical improvement by Day 28, and safety, adverse events and discontinuations were low and similar to placebo.
More than 400 patients have now received paridiprubart. Based partly on these results, Edesa has filed U.S. provisional patents covering use of paridiprubart in sepsis, acute kidney injury and pneumonia, adding to core composition-of-matter patents that extend into the 2030s. The drug is also being tested in a separate, government-funded ARDS study with enrollment of about 200 subjects for the company cohort.
Nantahala Capital Management and its principals reported a significant ownership position in Edesa Biotech. As of December 31, 2025, they may be deemed to beneficially own 855,583 common shares, representing 9.99% of the outstanding class. This total includes 230,583 shares that can be acquired within sixty days through convertible securities. Voting and dispositive power over all reported shares is shared among Nantahala, Wilmot B. Harkey, and Daniel Mack, with no sole authority. They certify the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Edesa Biotech.